The department is made up of over 50 quantitative scientists with the majority distributed between West Point, PA and Rahway, NJ. Co-location with our key discovery and development partners enables us to deliver on our purpose while flexible work arrangements enable our group to balance work and life.
The department has groups aligned to therapeutic areas (TAs) that create deeper understanding in TA biology, relevant clinical endpoints, patient populations and the competitive landscape. This allows us to optimally tailor our quantitative contributions to drive impact. In addition, a dedicated pharmacometrics group harbors deep modeling and simulation expertise and focuses on applying state-of-the-art quantitative approaches.
QP2 aims to deliver significant value through optimizing dosage, identifying opportunities to halt development of undifferentiated assets and streamlining the development of promising compounds and biologics, all of which contribute to life-changing therapies for patients. Our core strength has been in the areas of dose selection and characterization of pharmacokinetic (PK) and pharmacodynamic (PD) properties, while we continue to grow our strategy in areas such as informing the feasibility of targets in discovery, growing the impact of modeling in vaccine development and investing in advanced data science capabilities to enable the use of digital and real-world data.
Bringing together talent with multidisciplinary quantitative backgrounds and developing that talent to have deep therapeutic area expertise, robust technical skills, an understanding of the competitive landscape and end-to-end drug development experience.
Impacting a broad range of portfolio decisions that evolve over the arc of a program.
Placing high value on deliberate stakeholder engagement and maintaining key interfaces
across the discovery–development continuum.
Sharing our work both internally and externally via scientific presentations and publications.
